Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ULTI.OL
- Price
- 13.40
- Stock movement down
- -0.10 (-0.74%)
- Company name
- Ultimovacs ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 46.10M
- Ent værdi
- -60.12M
- Pris/omsætning
- -
- Pris/bog
- 0.24
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- 22.62%
- 1 års afkast
- -86.07%
- 3 års afkast
- -75.21%
- 5 års afkast
- -52.77%
- 10 års afkast
- -
Senest opdateret: 2025-04-10
UDBYTTE
ULTI.OL betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | - |
| Pris til egenkapital | 0.24 |
| EV i forhold til salg | - |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 3.44M |
| EPS (TTM) | -43.39 |
| FCF pr. aktie (TTM) | -52.65 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 0.00 |
| Bruttofortjeneste (TTM) | -2.96M |
| Driftsindkomst (TTM) | -162.35M |
| Nettoindkomst (TTM) | -149.28M |
| EPS (TTM) | -43.39 |
| EPS (1 år frem) | -10.81 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | - |
| Fortjenstmargin (TTM) | - |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 131.00M |
| Nettotilgodehavender | 0.00 |
| Omsætningsaktiver i alt | 140.07M |
| Goodwill | 11.74M |
| Immaterielle aktiver | 61.48M |
| Ejendomme, anlæg og udstyr | 2.49M |
| Sum aktiver | 215.79M |
| Kreditor | 4.08M |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 12.33M |
| Sum gæld | 24.78M |
| Aktionærernes egenkapital | 191.01M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -181.12M |
| Investeringsudgifter (TTM) | 17.00K |
| Fri pengestrøm (TTM) | -181.13M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -78.15% |
| Afkast af aktiver | -69.18% |
| Afkast af investeret kapital | -78.15% |
| Kontant afkast af investeret kapital | -94.83% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 13.99 |
| Daglig høj | 14.00 |
| Daglig lav | 13.21 |
| Daglig volumen | 22K |
| Højeste gennem alle tider | 1620.00 |
| 1 års analytiker estimat | 57.50 |
| Beta | 0.99 |
| EPS (TTM) | -43.39 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 5 May 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ULTI.OL | S&P500 | |
| Nuværende prisfald fra top notering | -99.17% | -19.00% |
| Højeste prisfald | -99.89% | -56.47% |
| Højeste efterår dato | 1 Apr 2025 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -46.28% | -11.07% |
| Gennemsnitlig tid til nyt højdepunkt | 37 days | 12 days |
| Maks. tid til nyt højdepunkt | 879 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
46.10M
Markedsværdi kategori
Small-cap
Beskrivelse
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Personale
17
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Norway
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WO...
28. februar 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WO...
13. februar 2025
Ultimovacs ASA (FRA:7UM) Q4 2024 Earnings Call Highlights: Strategic Merger and Financial Challenges
Despite significant financial losses and workforce reductions, Ultimovacs ASA's merger with Zelluna Immunotherapy aims to revolutionize cancer treatment with innovative TCRNK technology.
1. februar 2025
Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results toda...
31. januar 2025
Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourt...
27. januar 2025
Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i) 17 December 2024 regarding the contemplated business combination between the Co...
9. januar 2025
Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Compa...
19. december 2024
Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Compa...
19. december 2024
Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS...
17. december 2024
Reference is made to the stock exchange announcement by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business ...
17. december 2024
Næste side